Protein-protein interaction (PPI) network was constructed from down-regulated proteins and enriched with AKT and ERK1/2 as known biomarkers of acquired resistance to PLX4032 in BRAFV600E mutant CRC (Supplementary Figure S2), and BRAF and SPHK2 as specific pharmacological targets of PLX4032 and ABC294640, respectively. The gene discussed is SPHK2; the disease is colorectal carcinoma.